Recursion Pharmaceuticals Inc Class A RXRX
News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMAR, PANL, BALY, RXRX on Behalf of Shareholders
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders
Kuehn Law Encourages ITI, RXRX, GVP, and OBDE Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE on Behalf of Shareholders
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
Nvidia discloses positions in SoundHound AI, Arm - and these other stocks
Nvidia's stock breaks new ground after healthcare partnerships and ahead of CES
Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships
Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data